Latest News and Press Releases

MORRISVILLE, N.C., April 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, and Micheal Kaseta,...

On March 28, Judge Andrews removed the injunction issued in the Original Hatch Waxman LitigationOn March 29, Judge Bates denied United Therapeutics’ motion for temporary restraining order and...

Preparing to launch YUTREPIA™ (treprostinil) inhalation powder upon final FDA approvalFederal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent...

MORRISVILLE, N.C., March 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024. The...

MORRISVILLE, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today announced that the Company will present data from the L606 clinical program...

MORRISVILLE, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its...

MORRISVILLE, N.C., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today updates and promotions to its operations leadership in advance of the...

Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal CircuitRequests declaration that ‘327 patent is not infringed, is...

Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIAConfirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C.,...

Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placementAdditional advance of $25.0 million from HealthCare Royalty under current financing...